Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:MIST News 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·

Stock Market Today

KKR stock rebounds 4% after earnings shock; what investors watch before Monday’s open

KKR stock rebounds 4% after earnings shock; what investors watch before Monday’s open

8 February 2026
KKR shares jumped 4.06% to $103.20 Friday, rebounding from a steep drop the day before as trading volume surged. The firm disclosed a $1.4 billion deal to acquire Arctos and set an April 21 vote on governance changes, including a shift to one-vote-per-share by the end of 2026. Investors remain focused on KKR’s software exposure and loan leverage after an AI-driven selloff hit the sector.
Take-Two stock snaps back Friday — the next dates TTWO traders are watching

Take-Two stock snaps back Friday — the next dates TTWO traders are watching

8 February 2026
Take-Two Interactive shares closed up 1.22% at $195.59 Friday, trading between $189.45 and $198.07 on 3.1 million shares. The company reaffirmed Grand Theft Auto VI’s Nov. 19, 2026 release and raised its fiscal 2026 net bookings outlook to as much as $6.7 billion. The Dow closed above 50,000 for the first time.
Gold.com (GOLD) stock jumps nearly 10% as Tether deal and earnings reshape the week ahead

Gold.com (GOLD) stock jumps nearly 10% as Tether deal and earnings reshape the week ahead

8 February 2026
Gold.com, Inc. shares jumped 9.9% to $55.32 Friday after the company announced a $150 million share sale to Tether at an 11.9% discount, with $125 million closing first and the rest pending regulatory approval. Trading volume more than doubled the average. Gold.com posted Q2 revenue of $6.48 billion and net income of $11.6 million, and completed its Monex acquisition in January.
ASML stock price jumps as AI spending race returns; jobs data and dividend dates ahead

ASML stock price jumps as AI spending race returns; jobs data and dividend dates ahead

8 February 2026
ASML’s U.S.-listed shares jumped 4.6% to $1,413 on Friday, tracking a 5.7% rally in chip stocks after Amazon and Alphabet signaled higher AI infrastructure spending. Peers Applied Materials, Lam Research, and KLA each gained over 6%. ASML’s interim dividend goes ex-dividend Feb. 9 in Amsterdam and Feb. 10 in New York, with payment set for Feb. 18. U.S. jobs and inflation data are due next week.
Go toTop